Navigation Links
Dr. Lewis Cantley awarded $3 million breakthrough prize in life sciences
Date:2/21/2013

NEW YORK (Feb. 21, 2013) -- Dr. Lewis Cantley, a leading cancer researcher credited with discovering a family of enzymes fundamental to understanding cancer, was named a winner of the inaugural Breakthrough Prize in Life Sciences, the world's richest academic prize for medicine and biology. The prize, which carries a $3 million cash award, recognizes excellence in research aimed at curing intractable diseases and human life.

Dr. Cantley is director of the recently established Cancer Center at Weill Cornell Medical College and NewYork-Presbyterian Hospital and the Margaret and Herman Sokol Professor in Oncology Research and professor of cancer biology in medicine at Weill Cornell. Dr. Cantley was awarded the prize for his landmark discovery of the signaling pathway phosphoinositide 3-kinase (PI3K), which explains the growth of a cell and has major implications in cancer. His pioneering research discovered that human cancers frequently have mutations in PI3K and, for the past three decades, he has worked to identify new treatments for cancers that result from defects in this pathway.

Dr. Cantley is among a group of 11 recipients of the Breakthrough Prize, each receiving $3 million. The Breakthrough Prize in Life Sciences Foundation, a not-for-profit corporation dedicated to advancing breakthrough research, celebrating scientists and generating excitement about the pursuit of science as a career, will administer the prize. The awards were announced on February 20 in San Francisco, Calif., by the Foundation's chairman of the Board, Art Levinson, as well as the Foundation's founding sponsors, Yuri Milner, Sergey Brin, Anne Wojcicki, Mark Zuckerberg and Priscilla Chan.

"I am honored and deeply humbled to be selected for this prestigious award," Dr. Cantley said. "It's a privilege to be in the company of such absolutely spectacular scientists whose contributions have truly made a difference in the lives of patients. I'm very grateful to the Breakthrough Prize in Life Sciences Foundation for recognizing achievements that have defined my career."

All winners of the inaugural Breakthrough Prize in Life Sciences have agreed to serve on the Foundation's Selection Committee to choose recipients for future prizes. The Foundation plans to give five annually. The recipients have also been invited to present talks targeted for a general audience that will be made available to the public, enabling everyone to keep abreast of the latest development in life sciences.

"I am delighted for Dr. Cantley, whose groundbreaking research into the mechanisms that drive the development of cancer has led to landmark discoveries that have revolutionized the study and treatment of this devastating disease," says Dr. Laurie H. Glimcher, the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College. "This award is a testament to the excellence Dr. Cantley brings in cancer research at Weill Cornell."

As director of the Cancer Center at Weill Cornell Medical College and NewYork-Presbyterian, Dr. Cantley is leading efforts to employ precision medicine for cancer diagnosis and treatment. The Center ensures that patients can immediately benefit from the latest discoveries and treatments, especially in clinical trials, while training future researchers and recruiting leaders in cancer research and clinical care.

Dr. Cantley is a fellow of the American Academy of Arts and Sciences and a member of the National Academy of Sciences. He is one of the world's most pre-eminent scientists in both basic and clinical cancer research and a Cornell University alumnus. Dr. Cantley has made significant advances in cancer research stemming from his discovery of PI3K in the mid-'80s. This discovery, which has led to one of the most promising avenues for the development of personalized cancer therapies, has since resulted in revolutionary treatments for cancer, diabetes and autoimmune diseases.

Most recently, Dr. Cantley's research has focused on characterizing the mechanism by which PI3K is activated by growth factors and cancer-causing oncogenes, and elucidating PI3K's pathways, including Akt/PKB -- critical proteins that regulate cell survival and proliferation in normal and cancer cells. In the course of his work, Dr. Cantley's laboratory has revealed the structural basis for regulated interaction of these signaling proteins, and this technique has led to a bioinformatics approach for predicting signaling pathways on the basis of gene sequences.

Dr. Cantley is currently exploring the role of the PI3K pathway in cancer and diabetes. In 2011, he was awarded a $15 million grant from Stand Up 2 Cancer to lead a team of researchers to bring new cancer treatments to patients faster by investigating the role of PI3K in the development of breast, ovarian and endometrial cancers.

Dr. Cantley graduated summa cum laude in 1971 with a Bachelor of Science degree in chemistry from West Virginia Wesleyan College and obtained a Ph.D. in biophysical chemistry from Cornell University in 1975. He conducted postdoctoral research at Harvard University from 1975 until 1978, when he was appointed assistant professor of biochemistry and molecular biology at Harvard University's Faculty of Arts and Sciences. Dr. Cantley was appointed as professor of physiology at Tufts University in 1985, but returned to Harvard Medical School as professor of cell biology in 1992, a position he held until 2003.


'/>"/>

Contact: Lauren Woods
Law2014@med.cornell.edu
646-317-7401
Weill Cornell Medical College
Source:Eurekalert

Related medicine news :

1. Equity Annuities "Best of the Best" Awarded to Resource 4 Retirement for Excellence by Follow Media Consulting, Inc.
2. Physicians Hair Restoration Center's Dr. Carlos Puig Awarded Golden Follicle Award
3. Therapy Richmond VA "Best of the Best" Awarded to Good Neighbor Community Services for Excellence by Follow Media Consulting, Inc.
4. Dr. Donaldson Awarded the 2012 Consumers’ Choice Award
5. Marriage Counseling Virginia "Best of the Best" Awarded to Good Neighbor Community Services for Excellence by Follow Media Consulting, Inc.
6. North Shore-LIJ awarded $300,000 federal grant for prostate cancer research training
7. Boston college biologist awarded NIH grant to probe link between HIV and peripheral neuropathy
8. $5 million awarded in Sixth Starr Cancer Consortium Grant Competition
9. Twelfth annual Wiley Prize in Biomedical Sciences awarded
10. BettyMills.com Exceeds $1 Million of Snack Rewards Awarded to its Customers Through Unique Perks Program
11. Eric Reiman of Banner Alzheimers Institute awarded Potamkin Prize for Alzheimers research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... Wells ... facility enhancement of their 503A compounding pharmacy located in Ocala, Florida. , ... physicians and patients throughout the United States for high-quality human anti-aging and ...
(Date:1/19/2017)... ... January 19, 2017 , ... This month, the CEO and Clinical Director ... their drug rehab center in Delray Beach, Florida has been changed from Sober Living ... such as Philip Seymour Hoffman and Chris Farley are dying from heroin overdoses, but ...
(Date:1/19/2017)... ... 2017 , ... WhoHaha , a digital media company dedicated to creating ... to produce a three-part video series that uses humor to highlight ways to improve ... of AHA’s Healthy For Good™ movement, which is designed to inspire all Americans to ...
(Date:1/19/2017)... ... January 19, 2017 , ... Cosmetic Town, an online plastic surgery community, begins ... make it easier for their readers to get the information they desire. The procedures ... as the techniques used on those particular areas. , “We are excited to streamline ...
(Date:1/19/2017)... ... January 19, 2017 , ... Catalent ... for drugs, biologics and consumer health products, today announced that it will be ... leader in innovative excipients and drug delivery solutions to health industries worldwide. The ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 19, 2017 Pfizer joins ... Milner Therapeutics Consortium   Major research ... Cambridge   The Milner Therapeutics ... ) as a partner to the Milner Therapeutics Consortium. ... the efficient transfer of materials between industry and academia ...
(Date:1/19/2017)... 2017  ViewRay, Inc. (Nasdaq: VRAY ... clinical MRI-guided radiation therapy system, announced today that it ... million through a private placement of its common ... financing and was joined by certain of ViewRay,s ... Venture Partners, and an additional new institutional investor, ...
(Date:1/19/2017)... , Jan. 18, 2017 The ... Food and Drug Administration (FDA) for its release ... and population health decision makers can proactively share ... products as well as emerging therapies awaiting FDA ... mirrors consensus recommendations that AMCP developed during two ...
Breaking Medicine Technology: